



LABORATORY FINDINGS AND DIAGNOSTICS OF TBE

Tatjana Avšič Županc

Institute of Microbiology and Immunology

Faculty of Medicine

University of Ljubljana

SLOVENIA

ECDC EVD-LabNet Webinar 28 September 2022



TBE IN SLOVENIA

- TBE was first diagnosed in 1953 and it became notifiable disease in 1977
- 200-300 cases/year; (14/100.000 population)







Knap N. et all: numerous articles.



TBE CASE is DELINEATED by

EPIDEMIOLOGICAL CRITERIA

exposure to tick or consumption of unpasteurised dairy products

CLINICAL CRITERIA

symptoms/signs of inflammation of the CNS (e.g. meningitis, meningoencephalitis)

LABORATORY CRITERIA

an elevated cerebrospinal fluid cell count (> 5x 10⁶ cells/L)

MICROBIOLOGICAL CRITERIA

TBE specific IgM AND IgG antibodies in blood or TBE specific IgM antibodies in CSF Sero-conversion or 4-fold increase of specific antibodies in paired serum samples Detection of TBE viral nucleic acid in a clinical specimen Isolation of TBE virus from a clinical specimen



CLASSIC BIPHASIC DISEASE-PATTERN



FIRST PHASE

Non-specific symptoms – moderate fever, headache, body pain, fatigue, general malaise, nausea ... Meningeal signs absent Leukopenia and/or thrombocytopenia (~70%) Abnormal liver function tests (~20%) Normal CSF findings !!

Last 2 – 7 days



SECOND PHASE

CRP & blood leucocyte count normal/mildly elevated biochemical examinations usually within normal range

Pathological CSF findings !!

Elevated leucocytes (50–300 x 10⁶/L, lymphocytic predominance)

Normal glucose concentration

Normal/moderately elevated protein concentration



TBE – MICROBIOLOGICAL DIAGNOSTICS





FIRST PHASE DIAGNOSTICS

TBE viremia – EDTA blood, serum, urin – **PCR** and virus isolation 100 % RNA detection in serum/plasma/whole blood before seroconversion; only 16 % urine samples positive

No IgM or IgG antibodies in the initial phase of the disease!!!





FIRST PHASE DIAGNOSTICS

TBEV RNA was detected in the time frame of 1–14 (median 5) days from the beginning of the initial phase of illness

viral load ranged 3-6 log₁₀ RNA/ml (median 4.65)

no significant VL dynamic in initial phase





NO CORRELATION between viral load and duration of the first phase, duration of the asymptomatic interval, CSF cell count, leukocyte or platelet counts and clinical TBE severity



Saksida A. et all. EID 2018.



No direct association viral load and antibody response

But strong negative association between IgG and disease severity



Failure of rapid viral clearance may be resulting in a more pronounced infection of neuronal cells and subsequently in a more severe clinical presentation.



SECOND PHASE DIAGNOSTICS

SEROLOGY:

- Specific IgM and IgG antibodies
- Detection of antibodies in sera and CSF
- Standardized method

MOLECULAR DETECTION -

- No virus in the blood after the apperance of IgG antibodies
- Only in 16 % low level RNA detection in blood after IgM antibody appearance and in 6.6 % of urine samples
- no RNA detected in CSF in neurological phase

Dynamics of the diagnostic markers







SEROLOGICAL DIAGNOSTIC

Routine laboratory confirmation of TBEV infection is based on demonstration of:

- specific IgM and IgG antibodies in serum and/or CSF
- 4-fold increase in specific antibody response in serum
- intrathecal TBE-specific antibody response in CSF
- Seroconversion

Demonstration of IgM ALONE is not sufficient for the diagnosis!



- Standardized, automated method
- High sensitivity (IgM=98,8 %, IgG=99,5 %)
- High specificity (IgM=99,9 % (?), IgG =96,8%)
- Quantitative ELISA



Evaluation of serological methods ELISA



Sensitivity of the IgM TBEV ELISAs 94 – 100 % Specificity of the IgM TBEV ELISAs 94 – 100%

Sensitivity of the IgG TBEV ELISAs 87 – 94% Specificity of the IgG TBEV ELISAs 60 – 90%

Reusken C. et all.: J. Clin. Virol. 2019



Sensitivity^b

(96.8-100%)

80

81

83

82

(95% CI)

99.4%

172

141

3

0

Specificity

(95% CI)

(93.9-99.6%)

Specificity

96.4%

(89.8-99.3%)

98.8%

(93.4-100%)

97.9%

ReaScan TBE IgM rapid test



| Albinsson B. | et al | Euro | Surveill 2020 |
|--------------|-------|------|---------------|
|--------------|-------|------|---------------|



TICK BORNE ENCEPHALITIS – DIAGNOSTIC PITFALLS

CROSS-REACTIVITY

- exclusion of other viral exposure factors (vaccinations, travel to flavivirus endemic area)
- WNV, JEV, YFV, USUV, DENV, ZIKV
- neutralisation test, quantitative ELISA

VACCINATION BREAKTHROUGH

- Exclusion of other flavivirus infection
- Confirmation of CSF antibody formation
- Avidity testing for IgG antibodies
- TBE patients after vaccination have high avidity
- IgM antibodies are usually delayed!
- TBE NS1 specific antibodies only in infected, but not in vaccinated patients!
- Subsequent sera samples for confirmation of delayed IgM response, or an increase in specific IgG antibodies

Univerza v Ljubljani | Medicinska fakulteta INŠTITUT ZA MIKROBIOLOGIJO IN IMUNOLOGIJ

NS1- based serological assays for the detection of TBEV immune response



Mora-Cardenas E. et all. PLoS NTD 2020



DIFFERENTIAL DIAGNOSIS

The differential diagnosis of TBE is extensive and includes a wide variety of CNS infections and non-infectious diseases.

- In initial phase anaplasmosis and also gastroenteritis is a possible explanation
- In neurological phase:
 - differentiation from other aseptic meningitis (WNV, JEV, HSV, adenovirus, enterovirus...)
 - other tick-borne diseases: Lyme borreliosis, babesiosis, HGA, tularemia, rickettsioses
- Co-infections!!!



CHARACTERIZATION OF CYTOKINES/CHEMOKINES

24 cytokines and chemokines were measured with Luminex bead assays



81 patients

Bogovič P. et all. J. Clin. Med. 2019



Cytokines differed substantially according to the compartment

Innate and Th1 responses are occurring locally in CSF (markedly higher in CSF)

Th17 and **B cell** (generally higher in serum) responses may be triggered in systemic circulation



This findings provide new insights in immunopathogenesis of TBE and implicate innate and Th1 adaptive responses in clinical presentation and severity of acute illness.

Bogovič P. et all.: J. Clin. Med. 2019



DYNAMIC OF CYTOKINE RELEASE and association with the outcome of the diseases

Acute TBE: cytokines reached the highest levels on days 5–7 of the meningoencephalitic phase and decreased thereafter.

Duration of acute phase was correlated CXCL12 (B cell) and IL-27 (Th17).

Follow-up at 2 months: we found some differential expression of cytokines in serum, but none of the cytokines had a predictive value for early identification of patients who may develop PES

Follow-up at 2-7 years: interestingly, patients with PES had generally higher levels of innate cytokines and decreased levels of cytokines associated with Th1 and Th17 at the last visit

Laboratory characteristics of the initial and second phase of TBE



88 adult patients

| • | Phase 1 |
|---|---------|
| • | Phase 2 |

Comparison of laboratory blood parameters in both phases of TBE revealed that laboratory abnormalities consisting of low leukocyte and platelet counts and increased liver enzymes level were associated with the first phase of TBE and resolved thereafter.



Immune characteristics of the initial and second phase of TBE



In the **initial phase** of TBE, the primary finding in serum was a rather heterogeneous immune response involving innate (CXCL11), B cell (CXCL13, BAFF), and T cell mediators (IL-27 and IL-4). During the **second phase** of TBE, growth factors associated with angiogenesis (GRO-α and VEGF-A) were the predominant characteristic in serum, whereas innate and Th1 mediators were the defining feature of immune responses in **CSF.** These findings imply that distinct immune processes play a role in the pathophysiology of different phases of TBE and in different compartments.

Bogovič P.et all.: Emerging Microbes & Infections 2022

ACKNOWLEDGMENTS



Univerza v Ljubljani | Medicinska fakulteta INŠTITUT ZA MIKROBIOLOGIJO IN IMUNOLOGIJO Nataša Knap Gašper, Mateja Jelovšek, Ana Saksida, Miša Korva, Katarina Resman Rus



Petra Bogovič Stanka Lotrič-Furlan Franc Strle

Lara Lusa





iverza v Liubliani | Medicinska







₽ famnit UNIVE



RHEUMATOLOGY, ALLERGY AND IMMUNOLOGY

Klemen Strle

